In the lead-up to BIO, Cartherics’ COO, Dr Ian Nisbet was interviewed by BioSpectrum Asia to discuss the company’s innovative approach to cell therapy development. He discusses the transformative potential of CAR-NK cell therapies in treating solid tumours and endometriosis. These engineered natural killer cells, derived from iPSCs, are designed to target and eliminate cancer […]
Melbourne, Australia, 28 May 2025 – Cartherics Pty Ltd (“Cartherics” or “Company”), a biotechnology company focused on developing immune cell therapies for cancer and other diseases, announced today that Dr. Ian Nisbet, […]
Cartherics’ Chief Operating Officer, Dr. Ian Nisbet recently presented at the 3rd ANZ Biologics Festival at Crown Promenade in Melbourne. His presentation titled, ‘Building a Discovery-to-Clinic Company to Exploit the Full Power of Cell Therapies’ provided insights into Cartherics’ innovative approach to clinical manufacturing and cell therapy development.
The 3rd ANZ Biologics Festival brought together biopharma […]
At Emergence 2024, Cartherics’ COO, Dr Ian Nisbet was interviewed by Wholesale Investor. In the interview, Ian discusses the company’s cutting-edge strategies in combating solid tumours through cell-based immunotherapy. From leveraging stem cells to navigating regulatory pathways and entering clinical trials, Cartherics is on a mission to redefine cancer treatment. This interview highlights the challenges, […]
Cartherics is pleased to announce that it will be attending Emergence 2024 – The Era of Abundance investment conference at the Hilton Sydney next week.
The company’s CEO, Prof. Alan Trounson AO, will be presenting at 11:14 am on Wednesday 28th February. His presentation will discuss:
Cartherics is pleased to announce that Dr Ian Nisbet, Chief Operating Officer, will be presenting at Australia Biologics 2024 at Crown Promenade in Melbourne.
The Australia Biologics Festival aims to gather the innovators, pioneers and leaders in the biologics industry, including biologics, biosimilars, vaccines, cell and gene therapy (CGT) and evolving therapeutics, to showcase the […]
Commercialising science and technology is key to the continued growth of Australia’s vibrant life sciences industry. Translating research into real-world results has important implications for consumers and businesses alike.
Bio Connections Australia 2023 was held today at Crown Promenade Melbourne with an important focus on translation, drug development and expediting Australia’s science into commercialisation.
The forum […]
The 2023 Australia-China Science and Innovation Forum focused on leading-edge Australian and Chinese biomedical research collaborations and commercialisation. The forum was held at Monash University’s Suzhou campus in China last week and was also available for online attendance.
The forum’s program was designed to promote connections and enhance collaborations between the Australian and Chinese research and […]
Cartherics’ Director of IP & Licensing, Telma Mantas recently attended the ACI’s 21st Advanced Summit on Life Sciences Patents in New York City. The summit provided the opportunity to engage in face-to-face discussions with leading stakeholders on the best practices to enhance global protections for patent portfolios. Now more than ever in these increasingly […]
Cartherics’ mission is the development of novel, immune cell therapy products for the treatment of cancer, endometriosis and Alzheimer’s disease.
Stay informed about our latest news and developments
© Copyright 2022 | Cartherics Pty ltd
